Revolution Medicines, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $0 | $11.6M | $35.4M | $29.4M |
| Research and development | $987.3M | $592.2M | $423.1M | $253.1M | $186.9M |
| Operating expenses | $1.2B | $689.5M | $498.8M | $293.7M | $217.4M |
| Operating income | -$1.2B | -$689.5M | -$487.2M | -$258.3M | -$188.0M |
| Interest expense | $24.2M | $0 | $0 | $0 | $12,000 |
| Pretax income | -$1.1B | -$600.8M | -$439.9M | -$249.1M | -$187.1M |
| Income tax expense | $0 | -$753,000 | -$3.5M | -$420,000 | $0 |
| Net income | -$1.1B | -$600.1M | -$436.4M | -$248.7M | -$187.1M |
| Balance Sheet | |||||
| Cash and equivalents | $383.7M | $543.1M | $696.1M | $161.4M | $108.5M |
| Current assets | $2.1B | $2.3B | $1.9B | $660.2M | $589.8M |
| Total assets | $2.4B | $2.6B | $2.1B | $811.9M | $738.0M |
| Current liabilities | $290.4M | $163.9M | $143.9M | $62.0M | $60.4M |
| Total liabilities | $723.2M | $293.1M | $235.5M | $126.7M | $135.4M |
| Stockholders' equity | $1.6B | $2.3B | $1.8B | $685.2M | $602.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$897.7M | -$557.4M | -$350.6M | -$224.4M | -$147.2M |
| Depreciation and amortization | $7.8M | $6.6M | $5.0M | $4.0M | $3.1M |
| Stock-based compensation | $118.4M | $79.2M | $61.8M | $31.2M | $20.7M |
| Capital expenditure | $16.0M | $10.3M | $7.7M | $10.8M | $6.5M |
| Free cash flow | -$913.7M | -$567.7M | -$358.3M | -$235.2M | -$153.7M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 212.6M · Free float 92.7%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.